The government on Monday announced the introduction of a new class of innovative medication, known as GLP-1 agonists, into Malta's public healthcare system in a move aimed at improving the treatment of diabetes and obesity.

Health and Active Ageing Minister Jo Etienne Abela described the initiative as a significant step forward, following what he said was a careful evaluation process and consultation with healthcare professionals. The decision, he noted, is based on scientific evidence and long-term sustainability, reflecting a measured and responsible approach to healthcare investment.

GLP-1 agonists have shown positive results in helping patients manage Type II diabetes while also supporting weight loss. However, the minister stressed that the medication is not a standalone solution. Instead, it is intended to form part of a broader treatment strategy that includes physical activity, a balanced diet, and multidisciplinary support.

The first phase of the rollout will target around 2,000 patients who suffer from Type II diabetes and severe obesity, defined as a body mass index (BMI) of 40 or higher. This initial phase represents an investment of approximately €5 million.

Minister Abela highlighted the wide-ranging impact of both diabetes and obesity, noting that they affect not only physical health but also mental wellbeing and overall quality of life. He said the new approach seeks to address patients' needs holistically rather than focusing on a single condition in isolation.

The treatment programme will include ongoing monitoring and professional support to ensure that patients achieve sustainable and positive outcomes. Authorities also plan to expand the initiative gradually in the coming years, depending on results and available resources, while continuing to prioritise evidence-based practices.

The minister concluded that the measure reflects a modern vision for public healthcare, one that places the patient at the centre while balancing innovation with responsibility and sustainability.